KineMed pulls in $15M for Lou Gehrig’s disease
KineMed, an Emeryville, Calif., biotech developing a new treatment for amyotrophic lateral sclerosis, or Lou Gehrig’s disease, raised $15 million in a convertible note offering. See our story at VentureBeat Life Sciences here.
Next Story: Accelerator incubator raises $23M for new biotech investments
Previous Story: KineMed raises $15M for Lou Gehrig’s disease
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.